How Wells Fargo Currently Rates OncoMed Pharma (NASDAQ:OMED)
In recent note shared with investors and clients today, Wells Fargo analysts began issuing OncoMed Pharma (NASDAQ:OMED) coverage with “Outperform” rating.
Approximately 50,428 shares of stock traded hands. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has declined 18.35% since May 1, 2015 and is downtrending. It has underperformed by 15.57% the S&P500.
OncoMed Pharmaceuticals, Inc. is a clinical development-stage biopharmaceutical company. The company has a market cap of $587.71 million. The Firm focuses on discovering and developing protein therapeutics targeting cancer stem cells (CSCs). It currently has negative earnings. The Company’s product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells.
According to Zacks Investment Research, “OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States.” Get a free copy of the Zacks research report on Oncomed Pharmaceuticals Inc (OMED).